Published on
Apr 16, 2026
FDA accelerated approval path needs improvement, says ICER
The FDA's accelerated approval pathway has delivered some important new medicines to patients more quickly, but it is plagued by inconsistencies and a lack of transparency. That's the conclusion of a just-published report (PDF) from the influential …
Source:
pharmaphorum
-
Neutral
